2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6343 Defining clinically meaningful improvement in patient-reported fatigue and symptoms in polycythemia vera: Results from the phase 3 VERIFY study of rusfertide

Joseph Scandura, MD, PhD, Cristina Ivanescu2, Gaizka Perez3, Sarita Khanna, PhD4, Arturo Molina, MD, MS5, Molly McFatrich6, Meng Yang, PhD7
1 Weill Cornell Medicine, New York, New York, United States
2 IQVIA, Madrid, Spain
3 IQVIA, Madrid, Spain
4 Protagonist Therapeutics, Inc., Newark, California, United States
5 Protagonist Therapeutics, Inc., Newark, California, United States
6 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
7 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States

Introduction

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by erythrocytosis, increased thrombotic risk, and substantial symptom burden. Although patient-reported outcomes (PROs) are commonly included in MPN clinical trials, thresholds for meaningful within-patient improvement (MWPI) that represent a clinically meaningful improvement from the patient perspective remains unclear in PV. In the phase 3 VERIFY study (NCT05210790), fatigue and PV relevant symptoms were assessed using the 1) Patient-Reported Outcomes Measurement Information System Fatigue Short Form 8a (PROMIS Fatigue SF8a) T-score; 2) Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) 7-item Total Symptom Score (TSS7 - fatigue, night sweats, pruritus, abdominal discomfort, left-sided rib pain, early satiety, bone pain); 3) 4-item core PV symptom score (TSS4 - fatigue, night sweats, pruritus, abdominal discomfort); 4) Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF - single item assessing problems with concentration). This analysis aimed to estimate MWPI thresholds for these four PRO endpoints in the overall study population and among patients with moderate-to-severe symptoms at baseline in VERIFY. In addition, an independent analysis evaluated the proportion of patients achieving MWPI thresholds by treatment arm.

Methods

Blinded data from the 32-week double-blind period of VERIFY Part 1a were analyzed to derive MWPI. MFSAF v4.0 and MPN-SAF were completed daily; PROMIS Fatigue SF-8a was completed at screening, baseline, and Week 4, 12, 20, 28, 32. Patient Global Impression of Severity (PGI-S) and Patient Global Impression of Change (PGI-C) were prespecified primary anchors. EORTC QLQ-C30 item 29, assessing overall health, was evaluated as a supportive anchor. MWPI thresholds were estimated using anchor-based methods and supported by empirical cumulative distribution function analyses and distribution-based estimates. Thresholds were estimated in the overall population and in prespecified symptomatic cohorts by baseline severity cutoffs.

Results

Clinically meaningful improvement thresholds were established for all four PRO measures. At Week 32, with Week 20 providing supportive evidence as needed, prespecified PGI-S and/or PGI-C anchors showed sufficient associations with PRO change scores across four measures (all correlations exceeded prespecified 0.371). In the overall population, proposed MWPI thresholds – representing reductions in score that patients would perceive as meaningful, ranged from 6.60 to 6.70 points for the PROMIS Fatigue SF8a Total T-score, 6.03 to 6.73 points for MFSAF v4.0 TSS7, 4.01 to 4.72 points for MFSAF v4.0 TSS4, and 2 points for the MPN-SAF problems-with-concentration item. Anchor-based estimates consistently exceeded distribution-based estimates, supporting that these changes exceeded expected measurement variability. Among patients with moderate-to-severe symptoms at baseline, PGI-C–based analyses yielded larger MWPI thresholds: reductions of 6.75 to 9.30 points for PROMIS Fatigue SF-8a, 7.83 to 8.55 points for MFSAF v4.0 TSS7, 5.67 to 6.71 points for MFSAF v4.0 TSS4, and 2-3 points for the MPN-SAF problems-with-concentration item.

In an independent analysis of VERIFY, a greater proportion of patients receiving rusfertide than placebo achieved clinically meaningful improvement across all PRO measures from baseline at Week 32: PROMIS Fatigue SF8a Total T-score (27.2% vs 16.4%), MFSAF v4.0 TSS7 (20.4% vs 9.6%), MFSAF v4.0 TSS4 (21.1% vs 8.2%), and MPN-SAF concentration problems (26.5% vs 14.4%). Differences were larger among patients with moderate-to-severe baseline symptoms, with MWPI achieved by 42.0% vs 13.5%, 44.7% vs 12.5%, 45.1% vs 12.2%, and 44.9% vs 27.8%, respectively.

Conclusions

Anchor-based analyses established MWPI thresholds for key fatigue and symptom PROs in PV. These thresholds demonstrate that a greater proportion of patients treated with rusfertide experienced improvements they perceived as meaningful, contextualizing PRO scores beyond numerical changes. Given the central role of PROs in MPN clinical trials and regulatory decision-making, these findings represent an important advancement by providing one of the first patient-derived frameworks for interpreting whether changes in PRO endpoints reflect clinically meaningful benefit. This work supports patient-centered interpretation of efficacy outcomes in VERIFY and future PV clinical trials.

Joseph Scandura, MD, PhD: Karyopharm - Research Funding; SDP Oncology - Research Funding; Calico - Consultancy (Includes expert testimony); Axiom - Consultancy (Includes expert testimony); Protagonist - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)